Mycophenolate mofetil

Drug Profile

Mycophenolate mofetil

Alternative Names: CellCept; Cellcept Capsules; ME MPA; Munoloc; R99; RS-61443

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche Palo Alto LLC
  • Developer Aspreva Pharmaceuticals Corporation; Chugai Pharmaceutical; Roche Palo Alto
  • Class Acyclic acids; Fatty acids; Small molecules
  • Mechanism of Action Immunosuppressants; Inosine monophosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pemphigus vulgaris; Myasthenia gravis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Heart transplant rejection; Liver transplant rejection; Lung transplant rejection; Lupus nephritis; Pancreas transplant rejection; Renal transplant rejection; Transplant rejection
  • Discontinued Multiple sclerosis; Myasthenia gravis; Pemphigus vulgaris; Psoriasis

Most Recent Events

  • 14 May 2016 Launched for Lupus nephritis in Japan (PO, Capsule)
  • 14 May 2016 Launched for Lupus nephritis in Japan (PO, Powder)
  • 13 May 2016 Registered for Lupus nephritis in Japan (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top